<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131324</url>
  </required_header>
  <id_info>
    <org_study_id>DFD06-CD-007</org_study_id>
    <nct_id>NCT02131324</nct_id>
  </id_info>
  <brief_title>DFD06 Cream vs Comp01 Cream HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Parallel Group, Open Label, to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD06 Cream Versus Comp01 Cream in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promius Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promius Pharma, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA
      (hypothalamic-pituitary-adrenal) axis as compared to Comp01 cream when applied twice daily
      for 15 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects with HPA axis suppression.</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Comp01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>applied twice a day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFD06 Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>applied twice a day for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD06 Cream</intervention_name>
    <arm_group_label>DFD06 Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comp01</intervention_name>
    <arm_group_label>Comp01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque
        psoriasis.

        Subjects with psoriasis involving 20 to 50% BSA, not including the face, scalp, groin,
        axillae and other intertriginous areas.

        Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit Subjects
        whose results from the screening ACTH stimulation test are considered normal (cortisol
        level &gt;18 ug/dL at 30 minutes post stimulation) and show no other signs of abnormal HPA
        function or adrenal response

        Exclusion Criteria:

        Current diagnosis of unstable forms of psoriasis including guttate, erythrodemic,
        exfoliative or pustular psoriasis.

        History of organ transplant requiring immunosuppression, HIV, or other immunocompromised
        state.

        Have received treatment for any type of cancer within 5 years of the Baseline Visit except
        skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the
        Baseline Visit.

        Use within 60 days prior to the baseline Visit of: 1) immunosuppressive drugs (e.g.,
        tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g., methotrexate,
        cyclosporine, hydroxyurea) Use within 30 days prior to the Baseline Visit of: 1) topical
        antipsoriatic drugs (salicylic acid, anthralin, coal tar, calcipotriene), 2) PUVA therapy,
        3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine,
        6-thioguanine), or 4) UVB therapy.

        Use within 30 days prior to the Screening Visit of any product containing corticosteroids.
        Inhaled, intraocular, intranasal, etc. steroids are not allowed.

        Subjects who have an abnormal sleep schedule or work at night. Subjects with a known
        history of acute adrenal crisis, Addison's disease or decreased adrenal output, low
        pituitary function or pituitary tumors.

        Subjects who have a history of an adverse reaction to cosyntropin injection or similar
        test reagents.

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmela Fritz, MS</last_name>
    <email>cfritz@promiuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Agave Clinical Research, LLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan M Soo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Allan M Soo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Alonso-Llamazares, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Alonso-Llamazares, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Jimenez</last_name>
      <phone>954-430-1097</phone>
      <email>antonio.jimenez@fxmresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Moncada</last_name>
      <phone>954-430-1097</phone>
      <email>francisco.moncada@fxmresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco Flores, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belleair Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hue K. Luong</last_name>
      <phone>727-541-4431</phone>
      <email>huekluong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Chaundy</last_name>
      <phone>727-541-4431</phone>
      <email>schaundy@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Lee Heller, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Humeniuk, MD</last_name>
    </contact>
    <investigator>
      <last_name>John M Humeniuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>May 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
